We’re excited to announce that today, Berkeley Lights and IsoPlexis are moving forward together as PhenomeX, a premier functional cell biology company. Visit Site
See how our customers apply our antibody discovery workflow to solve real world problems.
Vanderbilt University on finding SARS-CoV-2 antibodies
ChemPartner on finding antibodies against membrane targets
Opto® Memory B Discovery on the Beacon® Optofluidic System enables rapid selection of lead molecules by function-forward screening of B cells from immunized animals in under 1 week. While Opto® Plasma B Discovery workflows enable screening of mouse plasma B cells, the Opto Memory B Discovery workflow enables rapid screening of rabbit memory B cells.
Rabbits have unique gene diversification strategies that produce antibodies with high affinity and specificity, making rabbit antibodies uniquely valuable reagents for basic research, diagnostics, and therapeutics development.1 Rabbit polyclonal antibodies are widely used for research applications; however, monoclonal antibodies are often preferred for diagnostic and therapeutic applications due to their well-defined specificity and stability.
Single B cell approaches are an attractive approach for discovery of rabbit monoclonal antibodies as compared with hybridoma and phage display owing to the low fusion efficiency and loss of cognate heavy/light chain pairing in the latter two approaches, respectively. A central challenge to single B cell screening in rabbits is the lack of robust B cell markers that enable purification of rabbit plasma B cells. As a result, rabbit B cell screening approaches are typically performed using memory B cells that must be activated to secrete antibodies for screening purposes.
As presented at Antibody Engineering & Therapeutics 2022, by Anupam Singhal, Ph.D., this presentation introduces Berkeley Lights’ newest antibody discovery workflow, the Opto® Memory B Discovery workflow, and shares how customers are using the workflow to screen rabbit memory B cells to rapidly discover rabbit monoclonal antibodies.
The Opto® Plasma B Discovery workflow on the automated Beacon® system enables high-resolution screening of plasma B cells with unprecedented speed.
Direct functional profiling of B cells enables discovery of 10-fold more antibodies against GPCRs and other high-value targets.
Access to different species and B cell compartments to screen greater biodiversity.
Screening throughput of up to 100,000 B cells from a single sample allows recovery of higher affinity antibodies.
Have high hit rates? No problem! Recover every one with OptoSeq Barcoded BCR.
OptoSeq™ Barcoded BCR enables linkage of sequence to function by dual optical and genetic barcoding. Fluorescence signatures of beads are decoded on the Beacon system prior to exporting into specific locations in well plates. The genetic barcodes read by NGS sequencing can then be mapped to each bead, linking every antibody sequence to its corresponding function.
Re-express >1,000 antibodies in 1 week without gene synthesis and cloning.
The Opto BCR Rapid Re-expression kit converts antibody sequences into molecules in just 1 week for plate-based confirmation assays. Amplified cDNA is cloned into expression constructs in one step, enabling expression of >1,000 antibodies for rapid functional confirmation.
Opto® B Discovery on the Beacon® optofluidic system enables rapid selection of lead candidates by function-forward screening of B cells in under 1 week. This presentation will introduce Berkeley Lights’ newest antibody discovery workflow, the Opto® Memory B Discovery workflow, and share how customers are using the workflow to screen rabbit memory B cells to rapidly discover rabbit monoclonal antibodies (as presented at Antibody Engineering & Therapeutics 2023).
Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows CROs to scale their business and rapidly deliver lead molecules even against difficult targets.
Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows Pharma to succeed against difficult targets and deliver best-in-class antibody therapeutics.
Panelists from Genovac, will present case studies of how they have leveraged their core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.
Ask us about purchase options including our new TechAccess Subscription.*